Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Impedimed Limited ( (AU:IPD) ) has shared an update.
Impedimed Limited has applied for quotation on the ASX of 299,566,200 fully paid ordinary shares under the code IPD, with an issue date of May 8, 2026. The application, lodged via an Appendix 2A, formalises the admission of these securities to trading, expanding the company’s quoted share base and potentially enhancing liquidity and access for investors.
The newly quoted securities arise from transactions previously notified to the market, aligning this step with earlier capital management disclosures. By moving these shares onto the official quotation, Impedimed reinforces its compliance with ASX listing rules and may broaden its capacity to fund ongoing operations and growth initiatives in its specialised medical technology niche.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.02 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
Impedimed Limited is an ASX-listed medical technology company focused on developing and commercialising diagnostic and monitoring devices. Its primary products use bioimpedance spectroscopy to assess fluid status and body composition, targeting applications such as chronic disease management and oncology care in hospital and outpatient settings.
Average Trading Volume: 4,804,588
Technical Sentiment Signal: Sell
Current Market Cap: A$16.31M
See more data about IPD stock on TipRanks’ Stock Analysis page.